Диссертация (1139693), страница 29
Текст из файла (страница 29)
– Vol. 461. – p. 107-116.159. Moayyedi P., Ford A. et al. The efficacy of probiotics in the treatment ofirritable bowel syndrome: a systematic review // Gut. – 2010. – Vol. 59. – Р. 32532160. Moraes-Filho JP, Quigley EM. The intestinal microbiota and the role of244probiotics in irritable bowel syndrome: a review. Arq Gastroenterol. 2015Dec;52(4):331-8161. Motzer S.A., Jarrett M., Heitkemper M.M.
et al. Natural killer cell function andpsychological distress in women with and without irritable bowel syndrome // BiolRes Nurs. – 2002. –Vol. 4. - №1. – p. 31-42.162. Motzer S.A., Jarrett M., Heitkemper M.M. et al. Natural killer cell function andpsychological distress in women with and without irritable bowel syndrome // BiolRes Nurs. – 2002. –Vol. 4.
– №1. – P. 31-42163. Muhammad S Sajid, Madhu Hebbar, Mirza K Baig, Andy Li, Zinu Philipose.Use of Prucalopride for Chronic Constipation: A Systematic Review and Metaanalysis of Published Randomized, Controlled Trials J Neurogastroenterol Motil.2016 Apr 29164. Murek, M., Kopic, S. and Geibel, J. (2010) Evidence for intestinal chloridesecretion. Exp Physiol 95: 478-479165. Nagasako C.K., Garcia Montes C, Silva Lorena SL, Mesquita MA.
Irritablebowel syndrome subtypes: Clinical and psychological features, body mass indexand comorbidities. Rev Esp Enferm Dig. 2016 Feb;108(2):59-64.166. O'Brien SM, Scott LV, Dinan TG. Cytokines: abnormalities in majordepressionandimplicationsforpharmacologicaltreatment//Hum.Psychopharmacol. – 2004. – Vol. 19. – № 6. – P. 397-403167.
Naseribafrouei A, Hestad K, Avershina E, et.al. Correlation between thehuman fecal microbiota and depression. Neurogastroenterol Motil. 2014Aug;26(8):1155-62168. Öhman L., Isaksson S., Lindmark A.C. et al. T-cell activation in patients withirritable bowel syndrome // Am J Gastroenterol. – 2009. – Vol. 104. - ¹ 5. – p.1205-12.169. Ohman L., Lindmark A.C., Isaksson S.
et al. Increased TLR2 expression onblood monocytes in irritable bowel syndrome patients // Eur. J. Gastroenterol.Hepatol. – 2012. – Vol. 24. – №4. – P. 398-405;170. O'Malley D. Neuroimmune Cross Talk in the Gut. Neuroendocrine and245neuroimmune pathways contribute to the pathophysiology of irritable bowelsyndrome. Am J Physiol Gastrointest Liver Physiol. 2016 Nov 1;311(5):G934G941.171.
Ortiz-Lucas M., Saz-Peiró P.,Sebastián-Domingo J. J. Irritable bowelsyndrome immune hypothesis. Part one: the role of lymphocytes and mast cells //Rev. Esp. Enferm, Dig. – 2010. - Vol. 102. - № 11. – p. 637-647.172. Osler W. The principles and practice of medicine: designed for the use ofpractitioners and students of medicine (1892), New York: D Appleton andcompany.173. Pan et al.
Central mechanisms of menthol-induced analgesia J Pharmacol ExpTher 2012Dec;343(3):661-72. doi: 10.1124174. Parodi A, Paolino S, Greco A. et al. Small intestinalbacterial overgrowth inrosacea: clinical effectiveness of its eradication . Clin Gastroenterol Hepatol 2008;6: 759–64. 6.175. Parodi A, Sessarego M, Greco A et al. Small intestinal bacterial overgrowth inpatients suffering from scleroderma: clinical effectiveness of its eradication. Am JGastroenterol 2008; 103:1257–62176. Perveen I, Rahman MM, Saha M, et.al.
Prevalence of irritable bowel syndromeand functional dyspepsia, overlapping symptoms, and associated factors in ageneral population of Bangladesh. Indian J Gastroenterol. 2014 May;33(3):265-73177. Piche T, Saint-Paul MC, Dainese R, Marine-Barjoan E, Iannelli A, MontoyaML, Peyron JF, Czerucka D, Cherikh F, Filippi J, et al. Mast cells and cellularityof the colonic mucosa correlated with fatigue and depression in irritable bowelsyndrome. Gut. 2008; 57 :468–473.178. Piche T.
Tight junctions and IBS--the link between epithelial permeability,low-grade inflammation, and symptom generation? Neurogastroenterol Motil.2014 Mar;26(3):296-302179. Pimentel M, Lembo A, Chey WD, et al. Rifaximin therapy for patients withirritable bowel syndrome without constipation.N Engl J Med 2011;364:22–32.180. Piscaglia Anna Chiara, Laterza Lucrezia, Cesario Valentina. Nodular lymphoid246hyperplasia: A marker of low-grade inflammation in irritable bowel syndrome?World J Gastroenterol.
Dec 14, 2016; 22(46): 10198-10209181. Placidi E, Marciani L, Hoad CL, Napolitano A, et.al. The effects ofloperamide, or loperamide plus simethicone, on the distribution of gut water asassessed by MRI in a mannitol model of secretory diarrhoea. Aliment PharmacolTher. 2012 Jul;36(1):64-73182. Planche T., Aghaizu A., Holliman R., et al. Diagnosis of Clostridium difficileinfection by toxin detection kits: A systematic review. Lancet Infect Dis 2008;8:777-84.183. Polouektova E., Kurbatova A., Demura T., Kuchumova S., Sheptulin A.,Kogan E., Shifrin O., Ivashkin V.Cytokines and tight junction proteinsexpression, and psychosomatic changes in patients with irritable bowel syndrome// Gut. - 2012.
- Vol.44. - suppl.3. - Abstract PO330184. Pozuelo M, Panda S, Santiago A. Reduction of butyrate- and methane-producing microorganisms in patients with Irritable Bowel Syndrome. Sci Rep.2015 Aug 4;5:12693185. Prior A, Maxton DG, Whorwell PJ.
Anorectal manometry in irritable bowelsyndrome: differences between diarrhoea and constipation predominant subjects //Gut. – 1990. – Vol. 31. – P. 458-62.186. Pyleris E., Giamarellos-Bourboulis E.J., Koussoulas B. Prevalence of smallintestinal bacterial overgrowth in a greek cohort: relationship with irritable bowelsyndrome // Gut.
– 2010. - Vol. 59. - A 19.187. Pyleris E, Giamarellos-Bourboulis EJ, Tzivras D, et.al. The prevalence ofovergrowth by aerobic bacteria in the small intestine by small bowel culture:relationship with irritable bowel syndrome. Dig Dis Sci. 2012 May;57(5):1321-9.188. Quigley EM.
Gut bacteria in health and disease. Gastroenterol Hepatol (N Y)2013;9:560-569.189. Quigley E., Thompson J. The motor response to intestinal resection: motoractivity in the canine small intestine following distal resection // Gastroenterology.– 1993. – Vol. 105. – P. 791-8247190. Rasmussen S, Jensen TH, Henriksen SL et.al. Overlap of symptoms ofgastroesophageal reflux disease, dyspepsia and irritable bowel syndrome in thegeneral population.
Scand J Gastroenterol. 2015 Feb;50(2):162-9191. Rateau J.G., Morgant G., Droy-Priot M.T., Parier J.L. A histological,enzymatic and water-electrolyte study of the action of smectite, a mucoprotectiveclay, on experimental infectious diarrhoea in the rabbit // Curr. Med. Res. Opin. –1982. – Vol. 8. – P. 233-41192. Regnard C, Twycross R, Mihalyo M, Wilcock A. Loperamide. J Pain SymptomManage. 2011;42:319–323193. Romero-Valdovinos M., Gudiño-Ramírez A., Reyes-Gordillo J. Interleukin-8and -10 gene polymorphisms in irritable bowel syndrome // Mol. Biol. Rep. –2012. – Vol. 39.
– P. 8837-43;),194. Ruepert L., Quartero A.O. et al. «Bulking agents, antispasmodics andantidepressants for the treatment of irritable bowel syndrome.», The CochraneCollaboration The Cochrane Library 2013, Issue 3195. Ruepert et al. Bulking agents, antispasmodics and antidepressants for thetreatment of irritable bowel syndrome. The Cochrane Collaboration The CochraneLibrary 2013, Issue 3196. Sarkar Amar, et.al.
Psychobiotics and the Manipulation of Bacteria–Gut–BrainSignals. Trends Neurosci. 2016 Nov;39(11):763-781197. Sears С.L. Enterotoxigenic Bacteroides fragilis: a Rogue among Symbiotes //Clin. Microbiol. Rev. – 2009. – Vol. 22. – P. 349–69.198. Shah E.D., Basseri R.J., Chong K., Pimentel M. Abnormal breath testing inIBS: a meta-analysis // Dig. Dis. Sci. – 2010. – Vol. 55. – P.
2441-9199. Shimura S., Ishimura N., Mikami H.. Small Intestinal Bacterial Overgrowth inPatientswithRefractoryFunctionalGastrointestinalDisorders.JNeurogastroenterol Motil 2016; 22(1): 60-68.200. Simrén M, Barbara G, Flint HJ, et al. Intestinal microbiota in functional boweldisorders: a Rome foundation report. Gut 2013;62:159-176.201. Singh N. et al. The murine caecal microRNA signature depends on the248presence of the endogenous microbiota // Int. J.
Biol. Sci. – 2012. – Vol. 8. – P.171-86202. Sobczak M., Salaga M., Storr MA, Fichna J.. Physiology, signaling, andpharmacology of opioid receptors and their ligands in the gastrointestinal tract:current concepts and future perspectives. J Gastroenterol. 2014; 49(1): 24–45203. Spiller R, Lam C. An update on post-infectious irritable bowel syndrome: roleofgenetics,immuneactivation,serotoninandalteredmicrobiome.JNeurogastroenterol Motil 2012;18:258-268.204. Steer T., Carpenter H., Tuohy K., Gibson G.R. Perspectives on the role of thehuman gut microbiota and its modulation by pro- and prebiotics // NutritionResearch Reviews.
– 2000. – Vol. 13. – P. 229–54.205. Sternini C, Patierno S, Selmer IS, Kirchgessner A. The opioid system in thegastrointestinal tract.Neurogastroenterol Motil. 2004 Oct;16 Suppl 2:3-16206. Tack J, Müller-Lissner S et al. Diagnosis and treatment of chronic constipation– a European perspective. // Neurogastroenterol Motil.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
